The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Open accessAbstract
BACKGROUND: There is evidence that medications or vitamins that increase the levels of brain catecholamines and protect against oxidative damage may reduce the neuronal damage and slow the progression of Alzheimer's disease. METHODS: We conducted a double-blind, placebo-controlled, randomized, multicenter trial in patients with Alzheimer's disease of moderate severity. A total of 341 patients received the selective monoamine oxidase inhibitor selegiline (10 mg a day), alpha-tocopherol (vitamin E, 2000 IU a day), both selegiline and alpha-tocopherol, or placebo for two years. The primary outcome was the time to the occurrence of any of the following: death, institutionalization, loss of the ability to perform basic activities of daily living, or severe dementia (defined as a Clinical Dementia Rating of 3). RESULTS: Despite random assignment, the baseline score on the Mini-Mental State Examination was higher in the placebo group than in the other three groups, and this variable was highly predictive of the primary outcome (P<0.001). In the unadjusted analyses, there was no statistically significant difference in the outcomes among the four groups. In analyses that included the base-line score on the Mini-Mental State Examination as a covariate, there were significant delays in the time to the primary outcome for the patients treated with selegiline (median time, 655 days; P=0.012), alpha-tocopherol (670 days, P=0.001) or combination therapy (585 days, P=0.049), as compared with the placebo group (440 days). CONCLUSIONS: In patients with moderately severe impairment from Alzheimer's disease, treatment with selegiline or alpha-tocopherol slows the progression of disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“To date, none of the tested compounds have proven effective (Sano et al., 1997; Petersen et al., 2005; Pham and Plakogiannis, 2005; DeKosky et al., 2008).”
From The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer’s disease (2011) · cites this paper as Sano et al., 1997
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Following a report of success of high-dose vitamin E in keeping late-stage AD patients out of long-term care facilities longer than patients on a placebo81, other studies with vitamin E have been less impressive70,78,80.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [81]
Experimental — accuracy not yet measuredIn the citing paper
“there were no concerning safely signals or increased mortality with high-dose vitamin E. 127,128”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [127]
In the citing paper
“high-dose vitamin E (1000 IU twice daily was the regimen tested) may be considered based on results of 2 RCTs that supported approximately 20% lower rate of ADL decline over approximately 2 to 3 years; there were no concerning safely signals or increased mortality with high-dose vitamin E. 127,128”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [127]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
A Simple Sequentially Rejective Multiple Test Procedure
(1979) · Scandinavian Journal of Statistics · doi:10.2307/4615733 · Cited by 21,526
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Blessed, G., Tomlinson, B. E., & Roth, M. (1968) · British Journal of Psychiatry · doi:10.1192/bjp.114.512.797 · Cited by 4,117
Pryor, W. A. (1976) · Cited by 1,876
Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease.
Smith, C. D., Carney, J. M., Starke-Reed, P. E., Oliver, C. N., Stadtman, E. R., Floyd, R. A., & Markesbery, W. R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.23.10540 · Cited by 1,296
Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group (1993) · New England Journal of Medicine · doi:10.1056/nejm199301213280305 · Cited by 1,222
A 30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients With Alzheimer's Disease
Knapp, M. J. (1994) · JAMA · doi:10.1001/jama.271.13.985 · Cited by 1,000
The Free Radical Theory of Aging
Harman, D. (2003) · Antioxidants and Redox Signaling · doi:10.1089/152308603770310202 · Cited by 935
Research works printed but not linked: 1
- Holm S, 1979, Scand J Stat, 6, 65
Cited by
Sorted by citations
Items 601–700 of 1,005
Silverman, D. H. S. (1999) · Clinical Positron Imaging · doi:10.1016/s1095-0397(99)00020-5 · Cited by 85
Disorders of Endogenous and Exogenous Antioxidants in Neurological Diseases
Korczowska-Łącka, I., Słowikowski, B. K., Piekut, T., Hurła, M., Banaszek, N., Szymanowicz, O., Jagodziński, P. P., Kozubski, W. P., Permoda-Pachuta, A., & Dorszewska, J. (2023) · Antioxidants · doi:10.3390/antiox12101811 · Cited by 84
Current Treatment and Recent Clinical Research in Alzheimer's Disease
Neugroschl, J. A., & Sano, M. (2010) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20165 · Cited by 84
Self-citationCan malondialdehyde be used as a biological marker of progression in neurodegenerative disease?
Dib, M., Garrel, C., Favier, A. E., Robin, V., & Desnuelle, C. (2002) · Journal of Neurology · doi:10.1007/s004150200025 · Cited by 84
Oxidative Modifications of α‐Synuclein
Ischiropoulos, H. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07466.x · Cited by 84
Cui, Z., Bu, W., Fan, W., Zhang, J., Ni, D., Liu, Y., Wang, J., Liu, J., Yao, Z., & Shi, J. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.06.056 · Cited by 83
Neuroprotective strategies in Alzheimer’s disease
Longo, F. M., & Massa, S. M. (2004) · NeuroRx · doi:10.1602/neurorx.1.1.117 · Cited by 83
Machine learning for improved diagnosis and prognosis in healthcare
Maity, N. G., & Das, S. (2017) · IEEE Aerospace Conference (AERO) · doi:10.1109/aero.2017.7943950 · Cited by 83
Ginkgo Biloba Extract and Long-Term Cognitive Decline: A 20-Year Follow-Up Population-Based Study
Amieva, H., Meillon, C., Helmer, C., Barberger‐Gateau, P., & Dartigues, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0052755 · Cited by 83
Stroke: roles of B vitamins, homocysteine and antioxidants
Sánchez‐Moreno, C., Jiménez‐Escrig, A., & Martin-Marco, A. (2009) · Nutrition Research Reviews · doi:10.1017/s0954422409990023 · Cited by 83
Anti-amyloidogenic therapies: strategies for prevention and treatment of Alzheimer’s disease
Hamaguchi, T., Ono, K., & Yamada, M. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-5599-9 · Cited by 83
Effect of gonadectomy on subsequent development of age-related cognitive impairment in dogs
Hart, B. L. (2001) · Journal of the American Veterinary Medical Association · doi:10.2460/javma.2001.219.51 · Cited by 83
Prasad, K. N. (2016) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2016.01.002 · Cited by 83
Combination Therapy of Donepezil and Vitamin E in Alzheimer Disease
Klatte, E. T., Scharre, D. W., Nagaraja, H. N., Davis, R. A., & Beversdorf, D. Q. (2003) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-200304000-00010 · Cited by 83
Symptomatic and Nonamyloid/Tau Based Pharmacologic Treatment for Alzheimer DiseasePreprint
Aisen, P. S. S., Cummings, J. L., & Schneider, L. S. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006395 · Cited by 83
Self-citationJodko-Piórecka, K., & Litwinienko, G. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.02.006 · Cited by 82
Clock Drawing: Analysis in a Retirement Community
Paganini‐Hill, A., Clark, L. J., Henderson, V. W., & Birge, S. J. (2001) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2001.49185.x · Cited by 82
Dunn, B. K., Richmond, E. S., Minasian, L. M., Ryan, A. M., & Ford, L. G. (2010) · Nutrition and Cancer · doi:10.1080/01635581.2010.509833 · Cited by 82
Trenkle, D., Shankle, W. R., & Azen, S. P. (2007) · Journal of Alzheimer s Disease · doi:10.3233/jad-2007-11309 · Cited by 82
Mitochondrial medicine for neurodegenerative diseases
Du, H., & Yan, S. S. (2010) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.01.004 · Cited by 82
Bayesian model averaging in meta-analysis: vitamin E supplementation and mortality
Berry, D. A., Wathen, J. K., & Newell, M. (2009) · Clinical Trials · doi:10.1177/1740774508101279 · Cited by 82
Monoamine oxidase: radiotracer development and human studies
Fowler, J. S. (2002) · Methods · doi:10.1016/s1046-2023(02)00083-x · Cited by 82
Experimental Therapeutics of Neurodegenerative Disorders: Unmet Needs
Shoulson, I. (1998) · Science · doi:10.1126/science.282.5391.1072 · Cited by 82
Treating neurodegeneration by modifying mitochondria: potential solutions to a “complex” problem
Swerdlow, R. H. (2007) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1676 · Cited by 81
Dimethyl Fumarate Modulation of Immune and Antioxidant Responses: Application to HIV Therapy
Gill, A. J., & Kolson, D. L. (2013) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2013007247 · Cited by 81
Li, X., Yu, Y., & Tu, Z. (2021) · Molecules · doi:10.3390/molecules26051202 · Cited by 80
Chen, L., Dar, N. J., Na, R., McLane, K. D., Yoo, K., Han, X., & Ran, Q. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.01.002 · Cited by 80
Dawn-Linsley, M., Ekinci, F. J., Ortiz, D., Rogers, E. J., & Shea, T. B. (2004) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2004.06.010 · Cited by 80
Cognitive impairment and oxidative stress in the elderly: Results of epidemiological studies
Berr, C. (2000) · BioFactors · doi:10.1002/biof.5520130132 · Cited by 80
Mazlan, M., Then, S., Top, G. M., & Ngah, W. Z. W. (2006) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2005.10.006 · Cited by 80
Hallmarks of protein oxidative damage in neurodegenerative diseases: focus on Alzheimer’s disease
Polidori, M. C., Griffiths, H. R., Mariani, E., & Mecocci, P. (2007) · Amino Acids · doi:10.1007/s00726-006-0431-x · Cited by 80
Weinstock, M., KIRSCHBAUM‐SLAGER, N., Lazarovici, P., Bejar, C., Youdim, M. B. H., & Shoham, S. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb03622.x · Cited by 80
Mullan, K., Williams, M. A., Cardwell, C. R., McGuinness, B., Passmore, P., Silvestri, G., Woodside, J. V., & McKay, G. J. (2017) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.06.006 · Cited by 79
Diverse Actions of Astrocytes in GABAergic Signaling
Ishibashi, M., Egawa, K., & Fukuda, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20122964 · Cited by 79
Role of Oxidative Stress and Antioxidants in Acquired Inner Ear Disorders
Kishimoto‐Urata, M., Urata, S., Fujimoto, C., & Yamasoba, T. (2022) · Antioxidants · doi:10.3390/antiox11081469 · Cited by 79
New drugs for Alzheimer's disease and other dementias
Bullock, R. A. (2002) · The British Journal of Psychiatry · doi:10.1192/bjp.180.2.135 · Cited by 79
Friedlander, A. H., Norman, D. C., Mahler, M. E., Norman, K. M., & Yagiela, J. A. (2006) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2006.0381 · Cited by 79
Chronic antioxidant therapy reduces oxidative stress in a mouse model of Alzheimer's disease
Siedlak, S. L., Casadesús, G., Webber, K. M., Pappolla, M. A., Atwood, C., Smith, M. A., & Perry, G. L. (2009) · Free Radical Research · doi:10.1080/10715760802644694 · Cited by 79
Pappolla, M. A., Smith, M. A., Bryant‐Thomas, T., Bazan, N., Petanceska, S. S., Perry, G. L., Thal, L. J., Sano, M., & Refolo, L. M. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)00841-9 · Cited by 78
Self-citationADCS Prevention Instrument Project: Overview and Initial Results
Ferris, S. H., Aisen, P. S. S., Cummings, J. L., Galasko, D. R., Salmon, D. P., Schneider, L. S. S., Sano, M. C., Whitehouse, P. J., Edland, S. D., & Thal, A. L. J. (2006) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000213870.40300.21 · Cited by 78
Self-citationImmunocytochemical evidence that amyloid β (1–42) impairs endogenous antioxidant systems in vivo
Kim, H., Yamada, K., Nitta, A., Olariu, A., Tran, M. H., Mizuno, M., Nakajima, A., Nagai, T., Kamei, H., Jhoo, W., et al. (2003) · Neuroscience · doi:10.1016/s0306-4522(02)00993-4 · Cited by 78
Current Therapeutic Options for Alzheimers Disease
Lleó, A. (2007) · Current Genomics · doi:10.2174/138920207783769549 · Cited by 77
Huang, M. Y., Xie, S., Jiang, N., Lan, J., Kong, L., & Wang, X. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.12.034 · Cited by 77
Nakaso, K., Tajima, N., Horikoshi, Y., Nakasone, M., Hanaki, T., Kamizaki, K., & Matsura, T. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.04.008 · Cited by 77
Determinants of platelet activation in Alzheimer's disease
Ciabattoni, G., Porreca, E., Febbo, C. D., Iorio, A. D., Paganelli, R., Bucciarelli, T., Pescara, L., Re, L. D., Giusti, C., Falco, A., et al. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.12.011 · Cited by 77
Rahim, N. S., Lim, S. M., Mani, V., Majeed, A. B. A., & Ramasamy, K. (2017) · Pharmaceutical Biology · doi:10.1080/13880209.2017.1280688 · Cited by 77
Filip, V., & Kolibás, E. (1999) · PubMed Central · Cited by 77
Evidence-based pharmacotherapy of Alzheimer's disease
Evans, J. G., Wilcock, G. K., & Birks, J. (2004) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704004444 · Cited by 77
Current and Emerging Pharmacological Treatment Options for Dementia
Ringman, J. M., & Cummings, J. L. (2006) · Behavioural Neurology · doi:10.1155/2006/315386 · Cited by 77
Koppal, T., Subramaniam, R., Drake, J., Prasad, M. R., Dhillon, H. S., & Butterfield, D. A. (1998) · Brain Research · doi:10.1016/s0006-8993(97)01466-2 · Cited by 77
Spotlight on Ferroptosis: Iron-Dependent Cell Death in Alzheimer’s Disease
Ashraf, A., & So, P. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00196 · Cited by 76
Yoo, J., Lee, J., Ahn, B., Han, J., & Lim, M. H. (2025) · Chemical Science · doi:10.1039/d4sc06762b · Cited by 78
Biesalski, H. K., Grune, T., Tinz, J., Zöllner, I., & Blumberg, J. B. (2010) · Nutrients · doi:10.3390/nu2090929 · Cited by 76
Montilla-López, P., Muñoz-Águeda, M. C., Feijóo, M., Muñoz-Castañeda, J. R., Bujalance, I., & Túnez‐Fiñana, I. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)02151-9 · Cited by 76
Prasad, K. N., Cole, W. C., & Prasad, K. C. (2002) · Journal of the American College of Nutrition · doi:10.1080/07315724.2002.10719249 · Cited by 76
Lu, R., Kallenborn-Gerhardt, W., Geißlinger, G., & Schmidtko, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0029240 · Cited by 76
Family Experiences in the Journey Through Dementia Diagnosis and Care
Teel, C. S., & Carson, P. (2003) · Journal of Family Nursing · doi:10.1177/1074840702239490 · Cited by 76
Yan, T., He, B., Wan, S., Xu, M., Yang, H., Xiao, F., Bi, K., & Jia, Y. (2017) · Scientific Reports · doi:10.1038/s41598-017-07407-1 · Cited by 76
Differential oxidation of apolipoprotein E isoforms and interaction with phospholipids
Jolivalt, C. G., Leininger‐Muller, B., Bertrand, P., Herber, R., Christen, Y., & Siest, G. (2000) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(99)00232-4 · Cited by 76
Nanotechnology to improve the Alzheimer’s disease therapy with natural compounds
Ramalho, M. J., Andrade, S., Loureiro, J. A., & do Carmo Pereira, M. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-019-00694-3 · Cited by 75
Polyphenolic Antioxidants and Neuronal Regeneration
Ataie, A., Ataie, R., & Shadifar, M. (2016) · Basic and Clinical Neuroscience Journal · doi:10.15412/j.bcn.03070201 · Cited by 75
Health-Promoting Strategies for the Aging Brain
Chen, S. T., Volle, D. C., Jalil, J., Wu, P., & Small, G. W. (2018) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2018.12.016 · Cited by 75
Protective effects of α-tocopherol and tiopronin against cisplatin-induced ototoxicity
Fetoni, A. R., Sergi, B., Ferraresi, A., Paludetti, G., & Troiani, D. (2004) · Acta Oto-Laryngologica · doi:10.1080/00016480410016559 · Cited by 75
Joshi, Y. B., & Praticò, D. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00436 · Cited by 75
Defining and labeling disease‐modifying treatments for Alzheimer's disease
Cummings, J. L. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2008.12.003 · Cited by 75
Antioxidants and herbal extracts protect HT-4 neuronal cells against glutamate-induced cytotoxicity
Kobayashi, M. S., Han, D., & Packer, L. (2000) · Free Radical Research · doi:10.1080/10715760000300121 · Cited by 75
Prasad, K. N., Hovland, A. R., Cole, W. C., Prasad, K. C., Nahreini, P., Edwards‐Prasad, J., & Andreatta, C. P. (2000) · Clinical Neuropharmacology · doi:10.1097/00002826-200001000-00002 · Cited by 75
Lowered plasma vitamin C, but not vitamin E, concentrations in dementia patients.
Charlton, K. E., Rabinowitz, T. L., Geffen, L., & Dhansay, M. A. (2004) · PubMed · Cited by 74
Pipingas, A., Silberstein, R. B., Vitetta, L., Rooy, C. V., Harris, E., Young, J. M., FRAMPTON, C. M. A., Sali, A., & Nastasi, J. V. (2008) · Phytotherapy Research · doi:10.1002/ptr.2388 · Cited by 74
McCullagh, C. D., Craig, D. W., McIlroy, S. P., & Passmore, A. P. (2001) · Advances in Psychiatric Treatment · doi:10.1192/apt.7.1.24 · Cited by 74
Krumova, K., Friedland, S. N., & Cosa, G. (2012) · Journal of the American Chemical Society · doi:10.1021/ja301680m · Cited by 74
Webster, L., Groskreutz, D., Grinbergs‐Saull, A., Howard, R. J., O'Brien, J. T., Mountain, G. A., Banerjee, S., Woods, B. T., Perneczky, R., Lafortune, L., et al. (2017) · Health Technology Assessment · doi:10.3310/hta21260 · Cited by 75
Elharram, A., Czegledy, N. M., Golod, M., Milne, G. L., Pollock, E. D., Bennett, B. M., & Shchepinov, M. S. (2017) · FEBS Journal · doi:10.1111/febs.14291 · Cited by 74
Neuroprotective effects of α-tocopherol on oxidative stress in rat striatal cultures
Osakada, F., Hashino, A., Kume, T., Katsuki, H., Kaneko, S., & Akaike, A. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01495-x · Cited by 74
Uberti, D. L., Carsana, T., Bernardi, E., Rodella, L. F., Grigolato, P., Lanni, C., Racchi, M., Govoni, S. M., & Memo, M. (2002) · Journal of Cell Science · doi:10.1242/jcs.115.15.3131 · Cited by 74
(‐)Deprenyl (Selegiline), a Catecholaminergic Activity Enhancer (CAE) Substance Acting in the Brain
Knull, J. (1998) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1998.tb01399.x · Cited by 74
Prevalence of potentially reversible dementias and actual reversibility in a memory clinic cohort.
Freter, S. H., Bergman, H., Gold, S. L., Chertkow, H. M., & Clarfield, A. M. (1998) · Europe PMC (PubMed Central) · Cited by 74
Kasote, D. M., Hegde, M. V., & Katyare, S. S. (2013) · BioFactors · doi:10.1002/biof.1093 · Cited by 73
Silvestrelli, G., Lanari, A., Parnetti, L., Tomassoni, D., & Amenta, F. (2005) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2005.09.018 · Cited by 73
Feldman, H., Schmitt, F. A., & Olin, J. T. (2006) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000213859.35355.59 · Cited by 73
dos Santos, J. I., Soares, A. M., & Fontes, M. R. M. (2009) · Journal of Structural Biology · doi:10.1016/j.jsb.2009.04.003 · Cited by 73
Vitamin E family: Role in the pathogenesis and treatment of Alzheimer's disease
Boccardi, V., Baroni, M., Mangialasche, F., & Mecocci, P. (2016) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.08.002 · Cited by 73
dos Reis, E. A., Zugno, A. I., Franzon, R. C., Tagliari, B., Matté, C., Lamers, M. L., Netto, C. A., & Wyse, Â. T. D. S. (2002) · Metabolic Brain Disease · doi:10.1023/a:1019982223034 · Cited by 73
N-Acetylcysteine delays age-associated memory impairment in mice: role in synaptic mitochondria
Martı́nez, M., Hernández, A. I., & Martínez-Banaclocha, N. (2000) · Brain Research · doi:10.1016/s0006-8993(99)02349-5 · Cited by 73
Patterson, C., Grek, A., Gauthier, S. G., Bergman, H., Cohen, C. A., Feightner, J., Feldman, H., & Hogan, D. B. (2001) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100001165 · Cited by 73
Recent Developments in the Drug Treatment of Alzheimer??s Disease
Sramek, J. J., & Cutler, N. R. (1999) · Drugs & Aging · doi:10.2165/00002512-199914050-00004 · Cited by 73
Presenilin-1 adopts pathogenic conformation in normal aging and in sporadic Alzheimer’s disease
Wahlster, L., Arimon, M., Nasser‐Ghodsi, N., Post, K. L., Serrano‐Pozo, A., Uemura, K., & Berezovska, O. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1065-6 · Cited by 72
Mudimu, O., Koopmann, I. K., Rybalka, N., Friedl, T., Schulz, R., & Bilger, W. (2017) · Journal of Applied Phycology · doi:10.1007/s10811-017-1188-1 · Cited by 72
Tschanz, J. T., Piercy, K. W., Corcoran, C. D., Fauth, E. B., Norton, M. C., Rabins, P. V., Tschanz, B. T., DeBerard, M. S., Snyder, C., Smith, C., et al. (2013) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2012.10.005 · Cited by 72
Weinstock, M., Gorodetsky, E. K., Poltyrev, T., Gross, A., Sagi, Y., & Youdim, M. B. H. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(03)00053-8 · Cited by 72
Overshott, R. (2005) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.082537 · Cited by 72
Cho, E. A., Lee, C. A., Kim, Y. S., Baek, S.-H., Reyes, B. G. D. L., & Yun, S. J. (2005) · Molecules and Cells · doi:10.1016/s1016-8478(23)13131-1 · Cited by 72
The Potential Role of Ferroptosis in Alzheimer’s Disease
Zhang, G., Zhang, Y.-R., Shen, Y., Wang, Y., Zhao, M. L., & Sun, L. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201369 · Cited by 71
Alzheimer’s Disease in 22 Twin Pairs – 13-Year Follow-Up: Hormonal, Infectious and Traumatic Factors
Nee, L. E., & Lippa, C. F. (1999) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000017115 · Cited by 71
The molecular mechanisms of the anti-amyloid effects of phenols
Shoval, H., Lichtenberg, D. A., & Gazit, E. (2007) · Amyloid · doi:10.1080/13506120601116674 · Cited by 71
Vitamin nutrition in older adults
Johnson, K. A., Bernard, M., & Funderburg, K. (2002) · Clinics in Geriatric Medicine · doi:10.1016/s0749-0690(02)00048-4 · Cited by 71
Alzheimer's disease and other dementias: A review
Rogan, S., & Lippa, C. F. (2002) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/153331750201700106 · Cited by 71
Vitamins in aging, health, and longevity
Thomas, D. R. (2006) · Clinical Interventions in Aging · doi:10.2147/ciia.2006.1.1.81 · Cited by 71
Neuronal plasticity and stressor toxicity during aging
Brewer, G. J. (2000) · Experimental Gerontology · doi:10.1016/s0531-5565(00)00121-2 · Cited by 71
Helmer, C., Peuchant, E., Letenneur, L., Bourdel‐Marchasson, I., Larrieu, S., Dartigues, J. F., Dubourg, L. D., Thomas, M., & Barberger‐Gateau, P. (2003) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1601724 · Cited by 71
Metadata
- Authors
- Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., Schneider, L. S., & Thal, L. J.
- Affiliations
- University of California San Diego (US)
- Harvard University (US)
- University of California, Irvine (US)
- University of South Florida (US)
- University of Southern California (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1997-04-24
- Volume
- 336
- Issue
- 17
- Pages
- 1216-1222
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2326200998
- Cited by
- 2,380
- References
- 36
- Citations by year
- 2026: 19 · 2025: 23 · 2024: 39 · 2023: 39 · 2022: 41 · 2021: 38 · 2020: 44 · 2019: 43 · 2018: 44 · 2017: 47 · 2016: 55 · 2015: 54 · 2014: 72 · 2013: 62 · 2012: 82
- FWCI
- 118.07
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (U01‐AG10483, U01AG010483, U19AG010483)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, selegiline, alpha-tocopherol, vitamin E, monoamine oxidase inhibitors, combination therapy, disease progression, dementia, activities of daily living, Mini-Mental State Examination, oxidative stress, catecholamines
- MeSH terms
- Activities of Daily Living, Aged, Alzheimer Disease, Cognition, Double-Blind Method, Drug Combinations, Female, Humans, Institutionalization, Male, Mental Status Schedule, Monoamine Oxidase Inhibitors, Selegiline, Vitamin E, Proportional Hazards Models, Treatment Outcome, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
